Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIONYSE / NASDAQHealthcareSmall cap

$23.85-$1.19 (-4.8%)

Last close · Data as of Nov 20, 2026

Market cap
$1.2B
P/E
-3.1x
EV / EBITDA
-2.8x
Revenue
$10.0M
Net margin
-3777.4%
ROCE
-65.9%

This period includes a one-day price step on 5 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Zenas BioPharma, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-15.4%
3M
-24.6%
6M
+21.9%
1Y
Hidden
5Y
Short history
  • This period includes a one-day price step on 5 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
  • A period is left blank when the price history is shorter than the period.

52-week range

This period includes a one-day price step on 5 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$1.19 (-4.8%) from $25.04 to $23.85 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ZBIO, bought on each weekday since 2024.

News & filings

What Zenas BioPharma filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 378 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 100.0% in fiscal 2025.
  • This period includes a one-day price step on 5 Jan 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.

Read moreShow less

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Shares outstanding
54.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.2B
P/E
-3.1x
P/B
4.8x
EV / EBITDA
-2.8x
EV / Sales
105.1x
P/S
116.0x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
-2113.8%
Net margin
-3777.4%
EBITDA margin
-3704.3%
ROE
-156.0%
ROCE
-65.9%
ROIC
-220.3%
ROA
-98.5%
Asset turnover
0.03

Growth

Revenue
$10.0M
Revenue growth, 1Y
100.0%
Net profit growth, 1Y
140.6%
Free cash flow
-$207.4M

Solvency

Current ratio
5.61
Debt / Equity
0.01
Debt / Assets
0.00
CFO / Net profit
0.46
Cash / Market cap
9.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$10.0M
Gross profit$10.0M
Operating expenses$221.4M
Research and development$168.1M
Selling, general and administrative$53.3M
Operating income-$211.4M
Interest and other-$166.4M
Pretax income-$377.8M
Tax and other-$80.0k
Net income-$377.7M

Revenue and net profit

Revenue grew 100.0% in FY2025; net profit is the dashed line.

Zenas BioPharma, Inc. revenue and net profit by fiscal year
Zenas BioPharma, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$119.3M
FY2023$50.0M-$37.1M
FY2024$5.0M-$157.0M
FY2025$10.0M-$377.7M

Cash flows

FY2025: -$172.3M from operations, -$207.4M free after investment (dashed).

Zenas BioPharma, Inc. operating and free cash flow by fiscal year
Zenas BioPharma, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$65.7M-$67.8M
FY2023-$30.5M-$30.5M
FY2024-$119.7M-$119.8M
FY2025-$172.3M-$207.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$10.0M+100.0%1Y
EBITDA
-$370.4M
Net profit
-$377.7M
Cash from operations
-$172.3M
Free cash flow
-$207.4M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$10.0M-$370.4M-$377.7M-$207.4M-156.0%+100.0%+140.6%

Monthly returns

Month-by-month returns of ZBIO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$383.6M
Liabilities$141.5M
Equity$242.1M
Paid-in capital$1.0B
Retained earnings-$765.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ZBIO highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Zenas BioPharma, Inc. (this company)105.1x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Zenas BioPharma, Inc.ZBIOthis company$1.2B-3.1x4.8x-156.0%-2.8x
IRADIMED CORPORATIONIRMD$1.2B53.2x12.6x23.8%41.9x
CareDx, Inc.CDNA$1.2B-55.9x3.9x-7.0%-248.1x
Kestra Medical Technologies, Ltd.KMTS$1.2B-10.5x5.8x-55.4%-10.2x
AMN Healthcare Services, Inc.AMN$1.2B—1.8x-14.9%19.3x
Schrödinger, Inc.SDGR$1.2B-11.5x3.3x-28.4%-6.6x
Wave Life Sciences Ltd.WVE$1.2B—2.3x-39.4%—
Avanos Medical, Inc.AVNS$1.2B—1.5x-9.4%—
Absci CorporationABSI$1.1B-9.9x6.0x-60.8%-10.9x
Peer median—-10.5x3.6x-21.6%-8.4x

Year-to-date ROI

ZBIO since 1 January, against earlier years.

Historical volatility

ZBIO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Zenas BioPharma, Inc. operating margin by fiscal year
Zenas BioPharma, Inc. operating margin by fiscal year
DateOperating margin
FY2023-54.3%
FY2024-3277.8%
FY2025-2113.8%
LineFY2025
Operating expensesOperating Expense$221.4M
Research and developmentResearch And Development$168.1M
Total expensesTotal Expenses$221.4M
Pretax incomePretax Income-$377.8M

Learn while you research

Academy chapters picked for Zenas BioPharma, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing100% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →